- Home
- SENEB vs RGNX Comparison
SENEB vs RGNX Comparison
Compare SENEB & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SENEB | RGNX |
|---|---|---|
| Founded | 1949 | 2008 |
| Country | United States | United States |
| Employees | N/A | 353 |
| Industry | Packaged Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 813.0M | 759.3M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | SENEB | RGNX |
|---|---|---|
| Price | $110.27 | $14.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $30.78 |
| AVG Volume (30 Days) | 447.0 | ★ 708.4K |
| Earning Date | 02-05-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.79 | N/A |
| EPS | ★ 8.61 | N/A |
| Revenue | ★ $1,606,175,000.00 | $161,318,000.00 |
| Revenue This Year | N/A | $132.80 |
| Revenue Next Year | N/A | $45.32 |
| P/E Ratio | $12.84 | ★ N/A |
| Revenue Growth | 8.33 | ★ 91.30 |
| 52 Week Low | $71.47 | $5.04 |
| 52 Week High | $124.94 | $15.80 |
Technical Indicators
Market Signals| Indicator | SENEB | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 50.40 | 56.86 |
| Support Level | $109.56 | $12.87 |
| Resistance Level | $115.00 | $15.80 |
| Average True Range (ATR) | 0.39 | 0.89 |
| MACD | -1.65 | 0.00 |
| Stochastic Oscillator | 9.78 | 60.75 |
Price Performance
Historical ComparisonAbout SENEB Seneca Foods Corp. Class B
Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.